Cargando…

Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies

PURPOSE: Complete metastasectomy of renal cell carcinoma (RCC) is receding into the past due to the progress of immuno-oncology-based combinations (IO) in systemic therapy. The prognostic impact of curative intended complete metastasectomy vs. immediate IO-based therapy or tyrosine kinase inhibition...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stühler, Viktoria, Herrmann, Lisa, Maas, Moritz, Walz, Simon, Rausch, Steffen, Stenzl, Arnulf, Bedke, Jens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085676/ https://www.ncbi.nlm.nih.gov/pubmed/35217885 http://dx.doi.org/10.1007/s00345-022-03960-1

Ejemplares similares

Real world data on IO-based therapy for metastatic renal cell carcinoma
por: Stühler, Viktoria, et al.
Publicado: (2022)

Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab
por: Stühler, Viktoria, et al.
Publicado: (2022)

The prognostic value of fat invasion and tumor expansion in the hilar veins in pT3a renal cell carcinoma
por: Stühler, Viktoria, et al.
Publicado: (2021)

Differential Expression and Clinical Relevance of C-X-C Motif Chemokine Receptor 4 (CXCR4) in Renal Cell Carcinomas, Benign Renal Tumors, and Metastases
por: Maas, Moritz, et al.
Publicado: (2023)

Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer
por: Hegemann, Miriam, et al.
Publicado: (2019)

Circulating tumor cells and their role in prostate cancer
por: Maas, Moritz, et al.
Publicado: (2019)

Performance of Urinary Markers for Detection of Upper Tract Urothelial Carcinoma: Is Upper Tract Urine More Accurate than Urine from the Bladder?
por: Bier, Simone, et al.
Publicado: (2018)

Tumour response in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors – assessment of intra-tumour heterogeneity
por: Stühler, Viktoria, et al.
Publicado: (2016)

MCT4 surpasses the prognostic relevance of the ancillary protein CD147 in clear cell renal cell carcinoma
por: Fisel, Pascale, et al.
Publicado: (2015)

Systemic Alterations of Wnt Inhibitors in Patients with Prostate Cancer and Bone Metastases
por: Aufderklamm, Stefan, et al.
Publicado: (2018)

A Peritoneal Purse-String Suture Prevents Symptomatic Lymphoceles in Retzius-Sparing Robot-Assisted Radical Prostatectomy
por: Harland, Niklas, et al.
Publicado: (2023)

Nicotinamide‐N‐methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma
por: Reustle, Anna, et al.
Publicado: (2022)

Clinical utility of the S3-score for molecular prediction of outcome in non-metastatic and metastatic clear cell renal cell carcinoma
por: Büttner, Florian, et al.
Publicado: (2018)

Bone Health Issues in Patients with Prostate Cancer: An Evidence-Based Review
por: Walz, Simon, et al.
Publicado: (2020)

Characterization of Genetic Heterogeneity in Recurrent Metastases of Renal Cell Carcinoma
por: Sauter-Meyerhoff, Carolin, et al.
Publicado: (2021)

Versatility and clinical effectiveness of a synthetic sealing hemostatic patch as alternative to parenchyma suturing in laparoscopic partial nephrectomy
por: Erne, Eva, et al.
Publicado: (2021)

Cytoreductive Nephrectomy and Nephrectomy/Complete Metastasectomy for Metastatic Renal Cancer
por: Russo, Paul, et al.
Publicado: (2007)

Current markers and their value in the era of immuno-oncology
por: von Rundstedt, Friedrich-Carl, et al.
Publicado: (2017)

The Significance of Metastasectomy in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy
por: Yu, Xiaoteng, et al.
Publicado: (2015)

A Rare Case of Synchronous Renal Cell Carcinoma of the Bladder Presenting With Gross Hematuria
por: Kruck, Stephan, et al.
Publicado: (2013)

Utility of pT3 substaging in lymph node-negative urothelial carcinoma of the bladder: do pathologic parameters add to prognostic sub-stratification?
por: Maas, Moritz, et al.
Publicado: (2021)

Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy
por: Reustle, Anna, et al.
Publicado: (2020)

Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy
por: Thaiss, Wolfgang M., et al.
Publicado: (2022)

Survival after initial lung metastasectomy for metastatic colorectal cancer in the modern chemotherapeutic era
por: Yokoyama, Shintaro, et al.
Publicado: (2017)

Artificial Intelligence-based Radiomics in the Era of Immuno-oncology
por: Kang, Cyra Y, et al.
Publicado: (2022)

Pulmonary metastasectomy in the era of targeted therapy and immunotherapy
por: Bong, Christopher Y., et al.
Publicado: (2021)

The hubris and humility of cancer pharmacology in the post immuno‐oncology era
por: Lazo, John S.
Publicado: (2019)

Checkpoint modulation - A new way to direct the immune system against renal cell carcinoma
por: Bedke, Jens, et al.
Publicado: (2015)

Immuno-Oncology
por: Chaudhuri, Swapna
Publicado: (2017)

The immuno-oncology framework: Enabling a new era of cancer therapy
por: Hoos, Axel, et al.
Publicado: (2012)

SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet Needs
por: Belluomini, Lorenzo, et al.
Publicado: (2022)

Oncological validation of bone turnover markers c-terminal telopeptide of type I collagen (1CTP) and peptides n-terminal propeptide of type I procollagen (P1NP) in patients with prostate cancer and bone metastases
por: Aufderklamm, Stefan, et al.
Publicado: (2021)

Biomarkers of Targeted Therapy and Immuno-Oncology in Cancers Metastatic to the Breast
por: Vranic, Semir, et al.
Publicado: (2020)

Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable
por: Vogl, U M, et al.
Publicado: (2006)

Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology
por: Kang, Sandra Mirie, et al.
Publicado: (2022)

Immuno‐Oncology in China
por: Lu, Shun, et al.
Publicado: (2019)

Radiomics in immuno-oncology
por: Bodalal, Z., et al.
Publicado: (2021)

Metastasectomy for Tumor-Infiltrating Lymphocytes: An Emerging Operative Indication in Surgical Oncology
por: Crompton, Joseph G., et al.
Publicado: (2017)

The Role of Radiation Oncology in Immuno‐Oncology
por: Meng, Xiangjiao, et al.
Publicado: (2019)

Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy
por: Bedke, Jens, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_nlumnv3u5i3sjl9g6d472vipkt